基于病情严重程度的新型冠状病毒肺炎患者用药模式及临床表现评价

K. Hema, Peddoju Moulika, Dinesh Kumar Kukunuri, Ganta Saidhulu, K. Dhivya, K. Karthik
{"title":"基于病情严重程度的新型冠状病毒肺炎患者用药模式及临床表现评价","authors":"K. Hema, Peddoju Moulika, Dinesh Kumar Kukunuri, Ganta Saidhulu, K. Dhivya, K. Karthik","doi":"10.26452/IJNTPS.V11I2.1412","DOIUrl":null,"url":null,"abstract":"Coronavirus disease of 2019 (COVID-19) is an extremely communicable disease characterized by the serious acute respiratory influenza virus 2, a recently identified novel viral disease (SARS-CoV-2). Hitherto, the quantity of established instances worldwide has reached 135 million, and the number of deaths is 2.9 million. In India, the cases were found to be 20 million and the mortality rate is 3,51,000. This virus was first identified in Wuhan City, Hubei Province in China, at the end of 2019. Until now, it affected more than 200 countries. The treatment pattern and clinical presentations were assessed in COVID 19 patients. A total of 146 patients, severe patients (n = 71) and non-severe patients (n = 75) where included in the study. The mean age of the study population was found to be 58.76±14.32 and the most common symptoms of patients include fever, fatigue, dry cough, and diarrhea there is no statistically significant difference in the clinical features between severe and non-severe patients. There is no significant difference in the laboratory findings except lymphocyte count, CORADS and N/L ratio between severe and non-severe patients. COVID-19 affects all age groups especially the elderly. The risk for severe illness with COVID-19 increases with age. COVID 19 patients were presented with various the risk factors and the clinical features in the severe and non severe conditions patients, our study shows great significance to prevent the patient turning to critical condition during diagnosis and treatment.","PeriodicalId":159799,"journal":{"name":"International Journal of Novel Trends in Pharmaceutical Sciences","volume":"47 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Evaluation of Drug Utilisation Pattern and Clinical Presentation in Covid19 Patients Based on the Disease Severity\",\"authors\":\"K. Hema, Peddoju Moulika, Dinesh Kumar Kukunuri, Ganta Saidhulu, K. Dhivya, K. Karthik\",\"doi\":\"10.26452/IJNTPS.V11I2.1412\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Coronavirus disease of 2019 (COVID-19) is an extremely communicable disease characterized by the serious acute respiratory influenza virus 2, a recently identified novel viral disease (SARS-CoV-2). Hitherto, the quantity of established instances worldwide has reached 135 million, and the number of deaths is 2.9 million. In India, the cases were found to be 20 million and the mortality rate is 3,51,000. This virus was first identified in Wuhan City, Hubei Province in China, at the end of 2019. Until now, it affected more than 200 countries. The treatment pattern and clinical presentations were assessed in COVID 19 patients. A total of 146 patients, severe patients (n = 71) and non-severe patients (n = 75) where included in the study. The mean age of the study population was found to be 58.76±14.32 and the most common symptoms of patients include fever, fatigue, dry cough, and diarrhea there is no statistically significant difference in the clinical features between severe and non-severe patients. There is no significant difference in the laboratory findings except lymphocyte count, CORADS and N/L ratio between severe and non-severe patients. COVID-19 affects all age groups especially the elderly. The risk for severe illness with COVID-19 increases with age. COVID 19 patients were presented with various the risk factors and the clinical features in the severe and non severe conditions patients, our study shows great significance to prevent the patient turning to critical condition during diagnosis and treatment.\",\"PeriodicalId\":159799,\"journal\":{\"name\":\"International Journal of Novel Trends in Pharmaceutical Sciences\",\"volume\":\"47 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Novel Trends in Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26452/IJNTPS.V11I2.1412\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Novel Trends in Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26452/IJNTPS.V11I2.1412","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

2019年冠状病毒病(COVID-19)是一种以严重急性呼吸道流感病毒2为特征的极传染性疾病,这是一种最近发现的新型病毒性疾病(SARS-CoV-2)。迄今为止,全世界已确定的病例数量已达到1.35亿例,死亡人数为290万人。在印度,发现的病例为2000万,死亡率为351,000。该病毒于2019年底在中国湖北省武汉市首次被发现。到目前为止,它已经影响了200多个国家。评估新冠肺炎患者的治疗方式和临床表现。研究共纳入146例患者,其中重症患者(n = 71)和非重症患者(n = 75)。研究人群的平均年龄为58.76±14.32岁,患者最常见的症状为发热、乏力、干咳、腹泻,重症与非重症患者的临床特征无统计学差异。除淋巴细胞计数、CORADS和N/L比值外,重症与非重症患者的实验室检查结果无显著差异。COVID-19影响所有年龄组,特别是老年人。患COVID-19严重疾病的风险随着年龄的增长而增加。COVID - 19患者在重症和非重症患者中呈现出各种危险因素和临床特征,我们的研究对预防患者在诊断和治疗过程中转危具有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluation of Drug Utilisation Pattern and Clinical Presentation in Covid19 Patients Based on the Disease Severity
Coronavirus disease of 2019 (COVID-19) is an extremely communicable disease characterized by the serious acute respiratory influenza virus 2, a recently identified novel viral disease (SARS-CoV-2). Hitherto, the quantity of established instances worldwide has reached 135 million, and the number of deaths is 2.9 million. In India, the cases were found to be 20 million and the mortality rate is 3,51,000. This virus was first identified in Wuhan City, Hubei Province in China, at the end of 2019. Until now, it affected more than 200 countries. The treatment pattern and clinical presentations were assessed in COVID 19 patients. A total of 146 patients, severe patients (n = 71) and non-severe patients (n = 75) where included in the study. The mean age of the study population was found to be 58.76±14.32 and the most common symptoms of patients include fever, fatigue, dry cough, and diarrhea there is no statistically significant difference in the clinical features between severe and non-severe patients. There is no significant difference in the laboratory findings except lymphocyte count, CORADS and N/L ratio between severe and non-severe patients. COVID-19 affects all age groups especially the elderly. The risk for severe illness with COVID-19 increases with age. COVID 19 patients were presented with various the risk factors and the clinical features in the severe and non severe conditions patients, our study shows great significance to prevent the patient turning to critical condition during diagnosis and treatment.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信